Search Clinical Trials
Sponsor Condition of Interest |
---|
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer...
National Cancer Institute (NCI)
Bladder Adenocarcinoma
Bladder Clear Cell Adenocarcinoma
Bladder Mixed Adenocarcinoma
Bladder Neuroendocrine Carcinoma
Bladder Small Cell Neuroendocrine Carcinoma
This phase II trial studies how well cabozantinib works in combination with nivolumab and
ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from
where it first started (primary site) to other places in the body. Cabozantinib may stop
the growth of tumor cells by blocking... expand
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib, nivolumab, and ipilimumab may work better in treating patients with genitourinary tumors that have no treatment options compared to giving cabozantinib, nivolumab, or ipilimumab alone. Type: Interventional Start Date: May 2019 |
Early PKD Observational Cohort Study
University of Kansas Medical Center
Polycystic Kidney Disease
This observational study will collect blood and urine and clinical information from
individuals with early-stages of polycystic kidney disease (PKD), their unaffected
siblings and normal volunteers to create a biobank, also called a biorepository. The
long-term goal is to develop new knowledge on... expand
This observational study will collect blood and urine and clinical information from individuals with early-stages of polycystic kidney disease (PKD), their unaffected siblings and normal volunteers to create a biobank, also called a biorepository. The long-term goal is to develop new knowledge on biological markers or biomarkers that indicate changes in the disease progression. An understanding of biomarkers for early renal cyst growth will benefit PKD patients as new therapies are being developed and tested. Type: Observational [Patient Registry] Start Date: Apr 2016 |
Quantitative Pulmonary Imaging Registry & Biorepository
University of Kansas Medical Center
Pulmonary Disease
The goal of this project is to establish a registry and biorepository of images and
biological samples from subjects undergoing novel pulmonary imaging methods to be used
for future research aimed toward identifying clinical applications of imaging methods and
toward understanding the physiological... expand
The goal of this project is to establish a registry and biorepository of images and biological samples from subjects undergoing novel pulmonary imaging methods to be used for future research aimed toward identifying clinical applications of imaging methods and toward understanding the physiological significance of imaging biomarkers. This registry and biorepository will accelerate the development of these imaging techniques and may lead toward future clinical adoption of quantitative pulmonary imaging. Type: Observational [Patient Registry] Start Date: May 2022 |
Developing Hyperpolarized 129Xe MRI Biomarkers for Evaluation of Pulmonary Arterial Hypertension
University of Kansas Medical Center
Pulmonary Arterial Hypertension
In this study, hyperpolarized 129Xe MRI will be used to evaluate treatment efficacy in
patients with pulmonary arterial hypertension (PAH). Participants will be imaged at 4
timepoints (baseline, 6 weeks post-therapy initiation, 12 weeks, and 18 weeks). Images
will be analyzed to develop new biomarkers... expand
In this study, hyperpolarized 129Xe MRI will be used to evaluate treatment efficacy in patients with pulmonary arterial hypertension (PAH). Participants will be imaged at 4 timepoints (baseline, 6 weeks post-therapy initiation, 12 weeks, and 18 weeks). Images will be analyzed to develop new biomarkers and to understand treatment effects. Type: Observational Start Date: Aug 2022 |
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent...
National Cancer Institute (NCI)
Pancreatic Acinar Cell Carcinoma
Pancreatic Adenosquamous Carcinoma
Pancreatic Squamous Cell Carcinoma
Resectable Pancreatic Acinar Cell Carcinoma
Resectable Pancreatic Adenocarcinoma
This phase II trial investigates how well the addition of olaparib following completion
of surgery and chemotherapy works in treating patients with pancreatic cancer that has
been surgically removed (resected) and has a pathogenic mutation in BRCA1, BRCA2, or
PALB2. Olaparib is an inhibitor of PARP,... expand
This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation in BRCA1, BRCA2, or PALB2. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Type: Interventional Start Date: Jun 2021 |
Using Microbiome to Predict Durvalumab Toxicity in Post- Concurrent Chemoradiation Therapy (CCRT) NSCLC...
Jun Zhang, MD, PhD
NSCLC, Stage III
Locally Advanced Lung Carcinoma
This phase IV study is hoping to determine if examining the microbiome in non-small cell
lung cancer participants who will receive durvalumab can predict treatment toxicity. expand
This phase IV study is hoping to determine if examining the microbiome in non-small cell lung cancer participants who will receive durvalumab can predict treatment toxicity. Type: Observational Start Date: Apr 2021 |
Evaluating the Tolerability and Effects of Berberine on Major Metabolic Biomarkers: A Pilot Study
University of Kansas Medical Center
Metabolic Syndrome
Berberine is a dietary supplement that comes from the roots, stems, and bark of various
plants and has been used for centuries in traditional Chinese medicine. It may help lower
cholesterol, lower blood sugar, and reduce inflammation.Very few studies have been done
in the United States to show how... expand
Berberine is a dietary supplement that comes from the roots, stems, and bark of various plants and has been used for centuries in traditional Chinese medicine. It may help lower cholesterol, lower blood sugar, and reduce inflammation.Very few studies have been done in the United States to show how berberine effects cholesterol and blood sugar. This study is looking to see how berberine changes cholesterol and blood sugar, and to see how well it is tolerated.Berberine is not a prescription medication but it appears to have similar actions to common prescription medications to lower cholesterol like statins, and to lower blood sugar like metformin. We are studying berberine to see if it may be a good option for people that do not want to take prescription medications. Type: Interventional Start Date: Aug 2019 |
Feasibility and Safety of Ketamine for Suicidal Patients in the Emergency Department
Lindsay Maguire, MD
Suicide
Suicidal Ideation
Depression
There is currently no readily available pharmacologic intervention for suicidal ideation,
a true psychiatric emergency, in the Emergency Department (ED). Investigators aim to
trial low-dose, intravenous ketamine, a drug with well-established use in
treatment-resistant depression, for patients who... expand
There is currently no readily available pharmacologic intervention for suicidal ideation, a true psychiatric emergency, in the Emergency Department (ED). Investigators aim to trial low-dose, intravenous ketamine, a drug with well-established use in treatment-resistant depression, for patients who present to the ED with suicidal ideation. Type: Interventional Start Date: May 2024 |
Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study
ECOG-ACRIN Cancer Research Group
Metastatic Renal Cell Carcinoma
Stage IV Renal Cell Cancer AJCC v8
This phase III trial compares the effect of stero-ablative radiotherapy (SAbR) followed
by standard of care systemic therapy, to standard of care systemic therapy alone, in
patients with kidney cancer that has spread from where it first started (primary site) to
a limited (2-5) number of places in... expand
This phase III trial compares the effect of stero-ablative radiotherapy (SAbR) followed by standard of care systemic therapy, to standard of care systemic therapy alone, in patients with kidney cancer that has spread from where it first started (primary site) to a limited (2-5) number of places in the body (metastatic). Study doctors want to find out if this approach is better or worse than the usual approach for metastatic kidney cancer. The usual approach is defined as the care most people get for metastatic kidney cancer which includes systemic therapy such as immunotherapy (given through the veins) and/or small molecular inhibitor (tablets taken by mouth). Radiotherapy uses high energy x-rays to kill cancer cells and shrink tumors. SAbR uses special equipment to position a patient and deliver radiation to tumors with high precision. Giving SAbR prior to systemic therapy may kill more tumor cells than the usual approach, which is systemic therapy alone. Type: Interventional Start Date: Sep 2023 |
AIRB-4: Self-Determined Learning Model of Instruction
Health Resources and Services Administration (HRSA)
Autism Spectrum Disorder
Neurodevelopmental Disorders
The AIRB research team will compare the use and effectiveness of each intervention (Mind
the Gap, Remaking Recess and Self Determined Learning Model of Instruction) with and
without the addition of our implementation strategy, UNITED. In all groups, the research
team will train community practitioners... expand
The AIRB research team will compare the use and effectiveness of each intervention (Mind the Gap, Remaking Recess and Self Determined Learning Model of Instruction) with and without the addition of our implementation strategy, UNITED. In all groups, the research team will train community practitioners using remote delivery of professional development modules specific to the intervention and active coaching as dictated by the intervention procedures. The research team will pair UNITED with three interventions that cover the ages of early childhood, childhood, and adolescence. These include Mind the Gap (MTG), a family navigation intervention for children newly diagnosed under age 8, Remaking Recess (RR), a school-based social/peer engagement intervention for children ages 5-12, and Self-Determination Learning Model of Instruction (SDMLI), a self-advocacy intervention for adolescents (13-22 years; 22 is the upper age limit of high school for individuals with disabilities). For the SDLMI, school personnel will be trained to work with adolescents with ASD using the SDLMI model. This model will help students with ASD set their own goals and help attain them. The total time commitment for the school personnel is 1 school year (2 semesters) for about 47 hours. The total time commitment for the parent of the student with ASD is about 1 hour (sign consent/fill out demographic survey). The total time commitment for the student with ASD is 1 school year (2 semesters) for about 25.25 hours. Type: Interventional Start Date: Aug 2021 |
US IDE Study of the Contour NEurovasCular Systemâ„¢ for IntraCranial Aneurysm Repair
Cerus Endovascular, Ltd
Aneurysm, Intracranial
The purpose of this trial is to gather data on the safety and effectiveness of the
Contour /Contour 021 System in the treatment of wide-necked bifurcated saccular,
intracranial aneurysms for submission to FDA in support of a premarket approval
application for the device. expand
The purpose of this trial is to gather data on the safety and effectiveness of the Contour /Contour 021 System in the treatment of wide-necked bifurcated saccular, intracranial aneurysms for submission to FDA in support of a premarket approval application for the device. Type: Interventional Start Date: Aug 2021 |
Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)
GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Pulmonary Arterial Hypertension
This open-label extension study will evaluate the long-term effects of GB002
(seralutinib) in subjects who previously participated in a GB002 PAH study. expand
This open-label extension study will evaluate the long-term effects of GB002 (seralutinib) in subjects who previously participated in a GB002 PAH study. Type: Interventional Start Date: Apr 2021 |
Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD)
University of Kansas Medical Center
FSHD
The primary goal of this proposal is to collect motor and functional outcomes specific to
FSHD over time. By collecting measures specific to FSHD, this will help ensure the best
level of clinical care is being provided. Also, the hope is to speed up drug development
by gaining a better understanding... expand
The primary goal of this proposal is to collect motor and functional outcomes specific to FSHD over time. By collecting measures specific to FSHD, this will help ensure the best level of clinical care is being provided. Also, the hope is to speed up drug development by gaining a better understanding of how having FSHD impacts motor function and other health outcomes (i.e. breathing, wheelchair use, etc.) and how big a change in motor function would be clinically meaningful to those with FSHD. Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD) will have approximately 450 FSHD participants followed for a minimum of 3 years. A subset of MOVE FSHD participants, approximately 200, will participate in the MOVE+ sub-study which includes whole body MRI and muscle biopsy. Type: Observational Start Date: Dec 2020 |
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2...
SWOG Cancer Research Network
Anatomic Stage IV Breast Cancer AJCC v8
Estrogen Receptor Positive
HER2/Neu Negative
Progesterone Receptor Positive
Prognostic Stage IV Breast Cancer AJCC v8
This randomized research trial studies how well serum tumor marker directed disease
monitoring works in monitoring patients with hormone receptor positive Her2 negative
breast cancer that has spread to other places in the body. Using markers to prompt when
scans should be ordered may be as good as... expand
This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread to other places in the body. Using markers to prompt when scans should be ordered may be as good as the usual approach to monitoring disease. Type: Interventional Start Date: Sep 2018 |
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
SWOG Cancer Research Network
Cardiotoxicity
HER2/Neu Positive
Metastatic Malignant Neoplasm in the Brain
Recurrent Breast Carcinoma
Stage IV Breast Cancer AJCC v6 and v7
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in
patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that
has spread to other places in the body. A beta-blocker, such as carvedilol, is used to
treat heart failure and high blood... expand
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy. Type: Interventional Start Date: Nov 2017 |
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma
Children's Oncology Group
Ganglioneuroblastoma
Localized Resectable Neuroblastoma
Localized Unresectable Neuroblastoma
Regional Neuroblastoma
Stage 4 Neuroblastoma
This research trial studies biomarkers in tumor tissue samples from patients with newly
diagnosed neuroblastoma or ganglioneuroblastoma. Studying samples of tumor tissue from
patients with cancer in the laboratory may help doctors identify and learn more about
biomarkers related to cancer. expand
This research trial studies biomarkers in tumor tissue samples from patients with newly diagnosed neuroblastoma or ganglioneuroblastoma. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. Type: Observational Start Date: Nov 2000 |
Sleep Health Enhancement in Midlife Adults
University of Kansas Medical Center
Sleep Health
Midlife Adults
Despite the strong links between sleep and AD, a sleep health enhancement has yet to be
targeted in mid-life adults (45-64 years old) to delay or prevent AD. An intervention
aimed at enhancing sleep health is a critical opportunity for primary prevention to
potentially delay the onset of AD. The objective... expand
Despite the strong links between sleep and AD, a sleep health enhancement has yet to be targeted in mid-life adults (45-64 years old) to delay or prevent AD. An intervention aimed at enhancing sleep health is a critical opportunity for primary prevention to potentially delay the onset of AD. The objective of the proposed study is to develop and assess the feasibility, acceptability, and treatment effect of a comprehensive sleep health intervention (SHI) on improving sleep health in mid-life adults Type: Interventional Start Date: Feb 2024 |
Peer Interventions for Preschoolers With Autism
University of Kansas
Autism Spectrum Disorder
This proposal will evaluate a series of peer-mediated interventions (PMIs) for preschool
children (3 to 6 years) with ASD and limited or no spoken language, using an innovative
Sequential Multiple Assignment Randomized Trial (SMART) design. Available evidence
supports the beneficial effects of PMIs... expand
This proposal will evaluate a series of peer-mediated interventions (PMIs) for preschool children (3 to 6 years) with ASD and limited or no spoken language, using an innovative Sequential Multiple Assignment Randomized Trial (SMART) design. Available evidence supports the beneficial effects of PMIs for improving social communication in children with ASD. Peer-related social competence is vital to a wide range of child outcomes, such as improved communication and fewer behavioral problems. Unfortunately, approximately 30% of children with ASD remain minimally-verbal in kindergarten, restricting participation in inclusive activities. Recent studies report improved communication after a speech-generating device (SGD) is included in treatment. Effective interventions that can be modified is necessary to ensure optimal communication outcomes when children do not make anticipated progress. A strength of the study is that these interventions can be adopted by community-based, early service providers. All participants will receive an adapted Stay-Play-Talk (SPT) peer-mediated intervention that varies in active ingredients. With SMART designs, it is possible to test and identify alternative combinations of PMI approaches, such as the addition of a SGD. In this study, 132 preschoolers with ASD (and N=264 peers without disabilities) will be initially randomized to SPT and SGD with spoken peer input only (SPT Basic; peers taught to model language) or SPT and SGD with augmented peer input (SPT Plus; peers taught to use verbal language models concurrently with the SGD). Each child's response to treatment after 5 weeks will determine that child's next phase in the SMART design. Children showing a positive response will continue in their originally assigned group; slow responders will be randomly assigned to receive added treatment components to improve communication (either SPT Plus or SPT Advanced). SPT Advanced adds direct instruction strategies (i.e., adult prompts, reinforcers, and teaching trials) to increase child vocalizations in SGD interventions. The use of a SMART design extends our prior work by testing the systematic addition of selected peer-mediated strategies in combination with an SGD that allows for flexible application of interventions based on child response. The investigators have assembled an outstanding team of highly qualified investigators with complementary skills in preschool assessment, language intervention, clinical trials, and statistics. Type: Interventional Start Date: Feb 2023 |
ALLIANCE: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve
Edwards Lifesciences
Aortic Stenosis, Severe
The objective of this study is to establish the safety and effectiveness of the Edwards
SAPIEN X4 Transcatheter Heart Valve (THV) in subjects with symptomatic, severe, calcific
aortic stenosis (AS). expand
The objective of this study is to establish the safety and effectiveness of the Edwards SAPIEN X4 Transcatheter Heart Valve (THV) in subjects with symptomatic, severe, calcific aortic stenosis (AS). Type: Interventional Start Date: Jun 2022 |
Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic...
University of Kansas Medical Center
Locally Advanced Cholangiocarcinoma
Metastatic Cholangiocarcinoma
Recurrent Cholangiocarcinoma
Stage III Hilar Cholangiocarcinoma AJCC v8
Stage III Intrahepatic Cholangiocarcinoma AJCC v8
This phase II trial tests how well sacituzumab govitecan works in treating patients with
cholangiocarcinoma that has spread to nearby tissue or lymph nodes (locally advanced),
that has come back after a period of improvement (recurrent) or that has spread from
where it first started (primary site)... expand
This phase II trial tests how well sacituzumab govitecan works in treating patients with cholangiocarcinoma that has spread to nearby tissue or lymph nodes (locally advanced), that has come back after a period of improvement (recurrent) or that has spread from where it first started (primary site) to other places in the body (metastatic). Sacituzumab govitecan is a monoclonal antibody, called hRS7, linked to a toxic agent, called SN-38. HRS7 is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of tumor cells, known as TROP2 receptors, and delivers SN-38 to kill them. Type: Interventional Start Date: Feb 2024 |
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung...
SWOG Cancer Research Network
Recurrent Lung Non-Small Cell Carcinoma
Stage IV Lung Cancer AJCC v8
This phase III trial compares the effect of the combination of ramucirumab and
pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell
lung cancer that is stage IV or that has come back after a period of improvement
(recurrent). Ramucirumab is a monoclonal antibody that... expand
This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help doctors find out if giving ramucirumab with pembrolizumab is more effective at treating patients with stage IV or recurrent non-small cell lung cancer than standard chemotherapy. Type: Interventional Start Date: Mar 2023 |
A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
Bellus Health Inc. - a GSK company
Refractory Chronic Cough
This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of
BLU-5937 in participants with Refractory Chronic Cough (RCC). expand
This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC). Type: Interventional Start Date: Oct 2022 |
The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-Versus-host Disease...
CSL Behring
Acute-graft-versus-host Disease
This study is a Phase 2/3 prospective, double-blind, randomized, multi-center,
placebo-controlled study for prevention of acute GVHD (aGVHD) in subjects undergoing an
allogeneic hematopoietic cell transplant (HCT). expand
This study is a Phase 2/3 prospective, double-blind, randomized, multi-center, placebo-controlled study for prevention of acute GVHD (aGVHD) in subjects undergoing an allogeneic hematopoietic cell transplant (HCT). Type: Interventional Start Date: Mar 2019 |
Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial
Johns Hopkins University
Multiple Sclerosis, Relapsing-Remitting
FDA-approved multiple sclerosis (MS) disease-modifying therapies (DMTs) target the
relapsing phase of MS but have minimal impact once the progressive phase has begun. It is
unclear if, in the relapsing phase, there is an advantage of early aggressive therapy
with respect to preventing long-term disability.... expand
FDA-approved multiple sclerosis (MS) disease-modifying therapies (DMTs) target the relapsing phase of MS but have minimal impact once the progressive phase has begun. It is unclear if, in the relapsing phase, there is an advantage of early aggressive therapy with respect to preventing long-term disability. The infectious risks and other complications associated with higher-efficacy treatments highlight the need to quantify their effectiveness in preventing disability. The TRaditional versus Early Aggressive Therapy for MS (TREAT-MS) trial is a pragmatic, randomized controlled trial that has two primary aims: 1) to evaluate, jointly and independently among patients deemed at higher risk vs. lower risk for disability accumulation, whether an "early aggressive" therapy approach, versus starting with a traditional, first-line therapy, influences the intermediate-term risk of disability, and 2) to evaluate if, among patients deemed at lower risk for disability who start on first-line MS therapies but experience breakthrough disease, those who switch to a higher-efficacy versus a new first-line therapy have different intermediate-term risk of disability. Type: Interventional Start Date: May 2018 |
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
Canadian Cancer Trials Group
Breast Cancer
The purpose of this study is to compare the effects on low risk breast cancer receiving
usual care that includes regional radiation therapy, with receiving no regional radiation
therapy. Researchers want to see if not giving this type of radiation treatment works as
well at preventing breast cancer... expand
The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back. Type: Interventional Start Date: Oct 2018 |
- Previous
- Next